SCHEMBL5543852

SCHEMBL5543852

CCCOC(=O)N1CCC[N]CC1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.44
POLB P06746 2/20 0.44
LMNA P02545 1/20 0.44
TSHR P16473 1/20 0.39
ALDH1A1 P00352 3/20 0.38
SMYD3 Q9H7B4 3/20 0.38
HTT P42858 1/20 0.38
GAA P10253 3/20 0.37
THRB P10828 1/20 0.36
ATM Q13315 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
RECQL P46063 1/20 0.36
OPRD1 P41143 1/20 0.35
KDM4E B2RXH2 1/20 0.35
FAAH O00519 1/20 0.34
MGLL Q99685 1/20 0.34
PDE4B Q07343 1/20 0.34
CNR2 P34972 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3953195 0.93 POLB (0.49) SMN1; SMN2POLBLMNATSHRALDH1A1
SCHEMBL5542964 0.89 SMN1; SMN2 (0.51) SMN1; SMN2POLBLMNATSHRALDH1A1
SCHEMBL2097634 0.88 TSHR (0.50) SMN1; SMN2POLBLMNATSHRALDH1A1
SCHEMBL5535309 0.88 LMNA (0.50) SMN1; SMN2POLBLMNATSHRL3MBTL1
SCHEMBL12311389 0.84 SMN1; SMN2 (0.53) SMN1; SMN2POLBLMNATSHRALDH1A1
SCHEMBL11480332 0.84 SMN1; SMN2 (0.53) SMN1; SMN2POLBLMNATSHRALDH1A1
SCHEMBL1937433 0.83 POLB (0.63) SMN1; SMN2POLBLMNATSHRALDH1A1
SCHEMBL1949240 0.82 SMN1; SMN2 (0.51) SMN1; SMN2POLBLMNATSHRALDH1A1
SCHEMBL7510677 0.81 POLB (0.57) SMN1; SMN2POLBLMNATSHRALDH1A1
SCHEMBL4687715 0.80 LMNA (0.55) SMN1; SMN2POLBLMNATSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 SMN1; SMN2 3985/4885POLB 1637/4885LMNA 4152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.